Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial DOI
Chao Wang, Tengyao Wang, Yuxia Chen

и другие.

Technology and Health Care, Год журнала: 2025, Номер unknown

Опубликована: Май 2, 2025

Background Drug treatment of refractory irritable bowel syndrome (IBS) is not satisfactory at present. This study investigated the clinical effects ebastine combined with low-dose antidepressants on IBS. Methods A total 105 patients IBS were randomly assigned to two different groups after signing informed consent. And they didn't know about group in. They administered (Group A) or flupentixol and melitracen B) for 4 weeks. efficacy was evaluated using scales before treatment. In addition, serum D-lactate (D-LAC) human intestinal fatty acid binding protein (I-FABP) level measured assess permeability. Results Significant improvements observed in Quality Life (IBS-QOL) score, Symptom Severity Scale (IBS-SSS) sleep quality score. Patients Group showed no anxiety (44.83 ± 9.62 vs. 43.92 10.43, P = 0.415) depression (39.08 9.34 38.75 9.35, 0.674) compared baseline level, while those B improved significantly (52.12 8.19 39.28 9.88) (47.64 9.53 38.24 9.41) status. After treatment, levels D-LAC I-FABP lower than A. Conclusion Refractory certain psychological abnormalities. Ebastine exhibited more obvious benefits QOL, quality, SSS, significant status permeability patients.

Язык: Английский

Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial DOI
Chao Wang, Tengyao Wang, Yuxia Chen

и другие.

Technology and Health Care, Год журнала: 2025, Номер unknown

Опубликована: Май 2, 2025

Background Drug treatment of refractory irritable bowel syndrome (IBS) is not satisfactory at present. This study investigated the clinical effects ebastine combined with low-dose antidepressants on IBS. Methods A total 105 patients IBS were randomly assigned to two different groups after signing informed consent. And they didn't know about group in. They administered (Group A) or flupentixol and melitracen B) for 4 weeks. efficacy was evaluated using scales before treatment. In addition, serum D-lactate (D-LAC) human intestinal fatty acid binding protein (I-FABP) level measured assess permeability. Results Significant improvements observed in Quality Life (IBS-QOL) score, Symptom Severity Scale (IBS-SSS) sleep quality score. Patients Group showed no anxiety (44.83 ± 9.62 vs. 43.92 10.43, P = 0.415) depression (39.08 9.34 38.75 9.35, 0.674) compared baseline level, while those B improved significantly (52.12 8.19 39.28 9.88) (47.64 9.53 38.24 9.41) status. After treatment, levels D-LAC I-FABP lower than A. Conclusion Refractory certain psychological abnormalities. Ebastine exhibited more obvious benefits QOL, quality, SSS, significant status permeability patients.

Язык: Английский

Процитировано

0